Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects

BACKGROUND: Niraparib is a highly selective poly (adenosine diphosphateribose) polymerase-1 and poly (adenosine diphosphate-ribose) polymerase-2 inhibitor indicated for select patients with ovarian, fallopian tube, and primary peritoneal cancer. The phase 2 GALAHAD trial (NCT02854436) demonstrated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Matthew R, Sandhu, Shahneen, George, Daniel J, Chi, Kim Nguyen, Saad, Fred, Thiery-Vuillemin, Antoine, Stàhl, Olaf, Olmos, David, Danila, Daniel C, Gafanov, Rustem, Castro, Elena, Moon, Helen, Joshua, Anthony M, Mason, Gary E, Espina, Byron M, Liu, Yan, Lopez-Gitlitz, Angela, Francis, Peter, Bevans, Katherine B, Fizazi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387937/
https://www.ncbi.nlm.nih.gov/pubmed/37404070
http://dx.doi.org/10.18553/jmcp.2023.29.7.758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387937/
https://www.ncbi.nlm.nih.gov/pubmed/37404070
http://dx.doi.org/10.18553/jmcp.2023.29.7.758

Ejemplares similares